Bulletin
Investor Alert

Market Pulse Archives

June 21, 2021, 9:29 a.m. EDT

Day One Biopharma's experimental glioma drug gets an orphan designation in Europe

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Day One Biopharmaceuticals Inc. (DAWN)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

DAWN

Shares of Day One Biopharmaceuticals Inc. /zigman2/quotes/227052400/composite DAWN +7.10% gained 9.4% in premarket trading on Monday after the company said its experimental glioma treatment received an orphan designation in Europe. The drug candidate has already received a Breakthrough Therapy designation from U.S. regulators for one indication and an orphan designation as a treatment for malignant glioma. In the U.S., an orphan-drug designation supports developing treatments for diseases that affect fewer than 200,000 people. Gliomas are a type of nervous system tumor. Day One went public last month.

/zigman2/quotes/227052400/composite
US : U.S.: Nasdaq
$ 22.01
+1.46 +7.10%
Volume: 82,524
Sept. 21, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$1.27 billion
Rev. per Employee
N/A
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.